Aridis Pharmaceuticals, Inc.
Aridis Pharmaceuticals is a biopharmaceutical company focused on developing novel, differentiated therapies for infectious diseases. They leverage proprietary technologies such as MabIgX® and pharmaceutical formulation technologies to produce anti-infective therapies, including monoclonal antibodies and small molecule anti-infectives. Their pipeline targets serious infections like pneumonia, resistant bacteria, and viral diseases, with a mission to combat antimicrobial resistance and viral pandemics.
Industries
Nr. of Employees
small (1-50)
Aridis Pharmaceuticals, Inc.
San Jose, California, United States, North America
Products
Human monoclonal IgG1 targeting Staphylococcus aureus alpha-toxin (clinical candidate)
A fully human IgG1 monoclonal antibody designed to neutralize S. aureus alpha-toxin to reduce host-cell destruction and serve as an adjunctive therapy to antibiotics for hospital-acquired and ventilator-associated pneumonia.
Broadly reactive anti-Pseudomonas human monoclonal IgG1 (clinical candidate)
A fully human IgG1 monoclonal antibody that binds to a widely distributed P. aeruginosa surface polysaccharide to enhance complement deposition and phagocytic killing; developed for adjunctive treatment of acute pneumonia and other P. aeruginosa infections.
Inhalable gallium-based anti-infective for lung infections (clinical-stage small molecule)
An inhalable formulation of gallium citrate that acts as an iron analog to inhibit bacterial iron-dependent pathways, intended to treat lung infections including cystic fibrosis-related infections and pneumonia.
Human monoclonal IgG1 targeting Staphylococcus aureus alpha-toxin (clinical candidate)
A fully human IgG1 monoclonal antibody designed to neutralize S. aureus alpha-toxin to reduce host-cell destruction and serve as an adjunctive therapy to antibiotics for hospital-acquired and ventilator-associated pneumonia.
Broadly reactive anti-Pseudomonas human monoclonal IgG1 (clinical candidate)
A fully human IgG1 monoclonal antibody that binds to a widely distributed P. aeruginosa surface polysaccharide to enhance complement deposition and phagocytic killing; developed for adjunctive treatment of acute pneumonia and other P. aeruginosa infections.
Inhalable gallium-based anti-infective for lung infections (clinical-stage small molecule)
An inhalable formulation of gallium citrate that acts as an iron analog to inhibit bacterial iron-dependent pathways, intended to treat lung infections including cystic fibrosis-related infections and pneumonia.
Services
Collaborative preclinical and clinical development partnerships
Collaborative programs supported by grant funding and partnerships to advance discovery-stage antibodies and small-molecule anti-infectives through preclinical development and into Phase 1–3 clinical trials.
Collaborative preclinical and clinical development partnerships
Collaborative programs supported by grant funding and partnerships to advance discovery-stage antibodies and small-molecule anti-infectives through preclinical development and into Phase 1–3 clinical trials.
Expertise Areas
- Monoclonal antibody discovery and development
- Clinical trial management for infectious-disease therapeutics
- Biomanufacturing and cell-line engineering
- Antibody engineering and optimization
Key Technologies
- Single-cell nanowell screening
- Hybridoma-based human mAb generation
- CRISPR-based gene editing and transcriptional activation
- CHO production cell-line engineering and site-specific integration